Hank Waterstein

New Emerging Biotech and Pharma Company Index

One of the more promising biotechs to come along in recent years is a platform technology company named Lpath, Inc. [LPTN, with a market cap of $50M-$60M]. They are the first (and only, I believe) company to ever generate monoclonal antibodies against bioactive-lipid targets, an emerging frontier in drug discovery.

They have two drug candidates in Phase 1, one of which is now partnered with Merck-Serono in a major worldwide collaboration.

HW